Deep Brain Stimulation for Advanced Parkinson Disease in Developing Countries: A Cost-Effectiveness Study From China.
Journal
Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
07
07
2022
accepted:
29
09
2022
pubmed:
3
2
2023
medline:
21
3
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
The cost-effectiveness of deep brain stimulation (DBS) is more favorable than best medical treatment (BMT) for advanced Parkinson disease (PD) in developed countries. However, it remains unclear in developing countries, where the cost of DBS may not be reimbursed by health care system. To model and evaluate the long-term cost-effectiveness of DBS for advanced PD in China from a patient payer perspective. We developed a Markov model representing the clinical progress of PD to predict the disease progression and related medical costs in a 15-year time horizon. The incremental cost-effectiveness ratio (ICER) and net benefit were used to evaluate the cost-effectiveness of DBS vs BMT. DBS treatment led to discounted total costs of ¥370 768 ($56 515.20) (95% CI, ¥369 621.53-371 914.88), compared with ¥48 808 ($7439.68) (95% CI, ¥48 502.63-49 114.21) for BMT, with an additional 1.51 quality-adjusted life years gained, resulting in an ICER of ¥213 544 ($32 549.96)/quality-adjusted life years (95% CI, ¥208 177.35-218 910.10). Sensitivity analysis showed that DBS-related cost has the most substantial impact on ICER. Nation-wide net benefit of BMT and DBS were ¥33 819 ($5154.94) (95% CI, ¥30 211.24-37 426) and ¥30 361 ($4627.85) (95% CI, ¥25 587.03-39 433.66), respectively. Patient demographic analysis showed that more favorable DBS cost-effectiveness was associated with younger age and less severe disease stage. DBS is cost-effective for patients with advanced PD over a 15-year time horizon in China. However, compared with developed countries, DBS remains a substantial economic burden for patients when no reimbursement is provided. Our findings may help inform cost-effectiveness-based decision making for clinical care of PD in developing countries.
Sections du résumé
BACKGROUND
The cost-effectiveness of deep brain stimulation (DBS) is more favorable than best medical treatment (BMT) for advanced Parkinson disease (PD) in developed countries. However, it remains unclear in developing countries, where the cost of DBS may not be reimbursed by health care system.
OBJECTIVE
To model and evaluate the long-term cost-effectiveness of DBS for advanced PD in China from a patient payer perspective.
METHODS
We developed a Markov model representing the clinical progress of PD to predict the disease progression and related medical costs in a 15-year time horizon. The incremental cost-effectiveness ratio (ICER) and net benefit were used to evaluate the cost-effectiveness of DBS vs BMT.
RESULTS
DBS treatment led to discounted total costs of ¥370 768 ($56 515.20) (95% CI, ¥369 621.53-371 914.88), compared with ¥48 808 ($7439.68) (95% CI, ¥48 502.63-49 114.21) for BMT, with an additional 1.51 quality-adjusted life years gained, resulting in an ICER of ¥213 544 ($32 549.96)/quality-adjusted life years (95% CI, ¥208 177.35-218 910.10). Sensitivity analysis showed that DBS-related cost has the most substantial impact on ICER. Nation-wide net benefit of BMT and DBS were ¥33 819 ($5154.94) (95% CI, ¥30 211.24-37 426) and ¥30 361 ($4627.85) (95% CI, ¥25 587.03-39 433.66), respectively. Patient demographic analysis showed that more favorable DBS cost-effectiveness was associated with younger age and less severe disease stage.
CONCLUSION
DBS is cost-effective for patients with advanced PD over a 15-year time horizon in China. However, compared with developed countries, DBS remains a substantial economic burden for patients when no reimbursement is provided. Our findings may help inform cost-effectiveness-based decision making for clinical care of PD in developing countries.
Identifiants
pubmed: 36729808
doi: 10.1227/neu.0000000000002274
pii: 00006123-202304000-00019
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
812-819Informations de copyright
Copyright © Congress of Neurological Surgeons 2022. All rights reserved.
Références
Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004;363(9423):1783-1793.
Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33-39.
Obeso JA, Stamelou M, Goetz CG, et al. Past, present, and future of Parkinson's disease: a special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017;32(9):1264-1310.
Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018;33(8):1248-1266.
Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging. 2010;5:229-238.
Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord. 2004;19(9):997-1005.
Lotia M, Jankovic J. New and emerging medical therapies in Parkinson's disease. Expert Opin Pharmacother. 2016;17(7):895-909.
Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord. 2015;30(1):80-89.
Chen W, Xiao Q, Shao M, et al. Prevalence of wearing-off and dyskinesia among the patients with Parkinson's disease on levodopa therapy: a multi-center registry survey in mainland China. Transl Neurodegener. 2014;3(1):26.
Hinnell C, Hurt CS, Landau S, Brown RG, Samuel M, Group P-PS. Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson's disease? Mov Disord. 2012;27(2):236-241.
Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896-908.
Pollak P, Benabid AL, Gross C, et al. Effects of the stimulation of the subthalamic nucleus in Parkinson disease. Rev Neurol (Paris). 1993;149(3):175-176.
Obeso JA, Olanow CW, et al.Deep-Brain Stimulation for Parkinson's Disease Study Group Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med. 2001;345(13):956-963.
Luquin MR, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES. Consensus on the definition of advanced Parkinson's disease: a Neurologists-Based Delphi Study (CEPA study). Parkinsons Dis. 2017;2017:4047392.
Antonini A, Moro E, Godeiro C, Reichmann H. Medical and surgical management of advanced Parkinson's disease. Mov Disord. 2018;33(6):900-908.
Kawamoto Y, Mouri M, Taira T, Iseki H, Masamune K. Cost-effectiveness analysis of deep brain stimulation in patients with Parkinson's disease in Japan. World Neurosurg. 2016;89:628-635.e1.
Dams J, Siebert U, Bornschein B, et al. Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease. Mov Disord. 2013;28(6):763-771.
Fundament T, Eldridge PR, Green AL, et al. Deep brain stimulation for Parkinson's disease with early motor complications: a UK cost-effectiveness analysis. PLoS One. 2016;11(7):e0159340.
Eggington S, Valldeoriola F, Chaudhuri KR, Ashkan K, Annoni E, et al. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease. J Neurol. 2014;261(1):106-116.
Valldeoriola F, Morsi O, Tolosa E, Rumia J, Marti MJ, Martinez-Martin P. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease. Mov Disord. 2007;22(15):2183-2191.
Pietzsch JB, Garner AM, Marks Jr WJ. Cost-Effectiveness of deep brain stimulation for advanced Parkinson's disease in the United States. Neuromodulation. 2016;19(7):689-697.
Fann JCY, Chang KC, Yen AMF, et al. Cost-effectiveness analysis of deep brain stimulation for Parkinson disease in Taiwan. World Neurosurg. 2020;138:e459-e468.
Zhu XL, Chan DT, Lau CK, et al. Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: a prospective study. World Neurosurg. 2014;82(6):987-993.
Zhang ZX, Roman GC, Hong Z, et al. Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet. 2005;365(9459):595-597.
Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384-386.
Li G, Ma J, Cui S, et al. Parkinson's disease in China: a forty-year growing track of bedside work. Transl Neurodegener. 2019;8(1):22.
Paulden M. Calculating and interpreting ICERs and net benefit. PharmacoEconomics. 2020;38(8):785-807.
Hoehn MM, Yahr M. Parkinsonism: onset, progression and mortality. Neurology. 2001;57(9):874.
Palmer CS, Schmier JK, Snyder E, Scott B. Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease. Qual Life Res. 2000;9(7):819-827.
Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896-908.
Liou HH, Wu CY, Chiu YH, et al. Mortality of Parkinson's disease by Hoehn–Yahr stage from community-based and clinic series [Keelung Community-based Integrated Screening (KCIS) no. 17]. J Eval Clin Pract. 2009;15(4):587-591.
Genever RW, Follett K, Stern M, et al. Deep brain stimulation for patients with advanced Parkinson disease. JAMA. 2009;301(19):1985-1986.
Awotwe I. Probabilistic One-Way Sensitivity Analysis: A Modified Tornado Diagram; 2016.
Pasricha SR, Gheorghe A, Sakr-Ashour F, et al. Net benefit and cost-effectiveness of universal iron-containing multiple micronutrient powders for young children in 78 countries: a microsimulation study. Lancet Glob Health. 2020;8(8):e1071-e1080.
Liu FT, Lang LQ, Yang YJ, et al. Predictors to quality of life improvements after subthalamic stimulation in Parkinson's disease. Acta Neurol Scand. 2019;139(4):346-352.
Yang JX, Chen L. Economic burden analysis of Parkinson's disease patients in China. Parkinson's Dis. 2017;2017:8762939.
Espay AJ, Vaughan JE, Marras C, Fowler R, Eckman MH. Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: a decision analysis. Mov Disord. 2010;25(10):1456-1463.
Gavriilaki M, Kimiskidis VK, Gavriilaki E. Precision medicine in neurology: the inspirational paradigm of complement therapeutics. Pharmaceuticals (Basel, Switzerland). 2020;13(11):341.